查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011246

小鼠模型市場：按模型類型、應用和最終用戶分類－2026-2032年全球市場預測

Mice Model Market by Model Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，小鼠模型市值將達到 17.4 億美元，到 2026 年將成長到 18.8 億美元，到 2032 年將達到 31.1 億美元，複合年成長率為 8.66%。

主要市場統計數據
基準年 2025 17.4億美元
預計年份：2026年 18.8億美元
預測年份 2032 31.1億美元
複合年成長率 (%) 8.66%

本文探討了創新小鼠模型如何發展成為現代非臨床研究框架內的重要資產。

生物醫學研究的進步已將小鼠模型從單純的實驗標本提升為支持現代治療方法發現的複雜平台。過去十年間，研究人員利用小鼠的遺傳柔軟性和生理有效性，以前所未有的精確度模擬了人類疾病。因此，這些模型已成為闡明分子路徑、檢驗藥物標靶和評估安全性的重要工具。

基因組編輯和人工智慧驅動的表現型分析的重大進展如何重新定義臨床前研究的範式。

受基因組編輯技術的突破、對轉化準確性的需求以及減少使用高等哺乳動物的倫理壓力等因素的推動，小鼠模型研究領域正經歷著變革性的轉變。 CRISPR-Cas9及相關基因編輯平台使得建立客製化基因敲除小鼠和人源化模型成為可能，從而縮短了研發週期並降低了成本。這些平台如今與先進的育種策略相結合，用於生產能夠模擬複雜人類疾病特徵的基因轉殖小鼠。

2025 年美國貿易措施的影響以及如何應對對確保模式採購和業務永續營運。

美國將於2025年實施並提高關稅，這不僅為小鼠模型生態系統帶來了挑戰，也帶來了調整的機會。進口科研耗材和專有繁殖個體的關稅增加了模型生產成本，迫使許多機構重新評估其供應鏈和供應商組合。研究機構和合約研究組織（CRO）正尋求透過整合訂單、協商長期供應合約以及投資本地繁殖設施來減輕財務負擔。

本研究旨在闡明模型物種的複雜性和應用主導的需求如何交織，並塑造獨特的研究路徑。

由於研究需求和資金優先事項各不相同，小鼠模型市場被細分為不同的類別，以滿足特定的實驗需求。近交系小鼠提供高度可重複的遺傳背景，是基礎研究的理想選擇；而非近交系小鼠則引入了反映人類群體的異質性，並支持毒性評估。在基因工程領域，條件性基因敲除可實現時間和組織特異性控制；基因改造小鼠表達外源基因用於通路分析；基因敲除模型透過完全去除基因來闡明基因功能；而人源化系統則模擬人類免疫動力學。

該評估了影響小鼠研究平台區域部署的區域研究生態系統和資金優先事項。

對區域趨勢的分析揭示了美洲、歐洲、中東和非洲以及亞太地區在研究投資、基礎設施和合作研究網路方面的細微差異。在美洲，健全的資金籌措體系和集中的生物技術中心正在促進垂直整合的供應舉措，從而實現先進小鼠模型的快速部署。北美研究聯盟和政府主導的措施正在推動官民合作關係，並加速科技的實用化。

繪製推動小鼠模型創新發展的競爭生態系統圖，該生態系統以技術領先地位和策略夥伴關係為特徵。

這項競爭格局匯集了專業的動物繁殖設施營運商、基因工程先驅和綜合服務供應商，他們都充分利用自身在技術整合、廣泛的產品組合和全球影響力方面的優勢。領先的實驗動物供應商正在擴展其基因庫，以涵蓋稀有基因敲除和人源化品系，並輔以合約繁殖服務，從而實現快速擴充性和客製化的群體管理。

為相關人員制定策略指南方針，以增強臨床前模型的韌性並加速創新

產業領導者應優先投資在地化養殖基礎設施，以降低貿易風險並防止供應中斷。建立具有可擴展能力的區域性畜牧中心可以縮短前置作業時間，並提高對突發研究計畫的應對力。同時，促進與基因組編輯專家的合作可以簡化針對特定治療標靶的客製化模型開發流程。

詳細介紹一個穩健的混合研究框架，該框架利用一手訪談和全面的二手資料檢驗。

我們的分析融合了多層次的調查方法，包括一手和二手資料收集、嚴格的檢驗以及三角測量。首先，我們仔細審查二級資訊來源，例如同行評審的文獻、專利資料庫、監管文件和行業白皮書，以確定基礎背景並識別新趨勢。

將洞察力融入協作創新和策略遠見，以塑造小鼠研究模型的未來。

小鼠模型處於科學創新、倫理考量和商業性需求的交會點。基因組編輯、數位表現型分析和區域投資策略等領域的不斷發展趨勢凸顯了該市場瞬息萬變的現狀，既充滿變革，也蘊藏著無限機會。積極應對供應鏈脆弱性並擁抱新興技術的相關人員，將更有能力引領下一波臨床前研究的突破性進展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：小鼠模型市場：依模型類型分類

  • 基因改造小鼠模型
    • 條件性敲除模型
    • 人源化小鼠模型
    • 淘汰賽模特兒
    • 基因改造模型
  • 近交系小鼠模型
  • 非近交系小鼠模型

第9章：小鼠模型市場：依應用分類

  • 行為研究
  • 心血管疾病
  • 藥物發現與毒理學
  • 遺傳疾病調查
  • 免疫學
  • 感染疾病
  • 代謝性疾病
  • 神經系統疾病與神經退化性疾病
  • 腫瘤學研究

第10章：滑鼠模型市場：依最終使用者分類

  • 學術和研究機構
  • 合約研究組織（CRO）
  • 醫院和診斷中心
  • 製藥和生物技術公司

第11章 小鼠模型市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 小鼠模型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：小鼠模型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國小鼠模型市場

第15章：中國小鼠模型市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Applied StemCell, Inc.
  • Aragen Life Sciences Ltd.
  • Biocytogen Boston Corporation
  • Charles River Laboratories International, Inc.
  • Creative Biolabs
  • Crown Bioscience by JSR Life Sciences, LLC
  • Cyagen US Inc. by PolyGene AG
  • Envigo by Inotiv, Inc.
  • GenOway
  • Harbour BioMed
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Marshall BioResources
  • MD Biosciences
  • Mirimus, Inc.
  • Ozgene Pty Ltd.
  • PhoenixBio Co., Ltd.
  • Shanghai Model Organisms Center, Inc.
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • TransCure bioServices
  • Translational Drug Development, LLC
  • Urosphere SAS
  • XenOPAT SL by Bellvitge Biomedical Research Institute
Product Code: MRR-4316E4E89369

The Mice Model Market was valued at USD 1.74 billion in 2025 and is projected to grow to USD 1.88 billion in 2026, with a CAGR of 8.66%, reaching USD 3.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.74 billion
Estimated Year [2026] USD 1.88 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 8.66%

Exploring how innovative murine systems have evolved to become indispensable assets in contemporary preclinical research frameworks

Advancements in biomedical research have elevated the role of murine systems from simple laboratory specimens to sophisticated platforms that underpin modern therapeutic discovery. Over the past decade, researchers have harnessed the genetic malleability and physiological relevance of mice to model human diseases with ever-increasing fidelity. As a result, these models have become indispensable tools for elucidating molecular pathways, validating drug targets, and assessing safety profiles.

In parallel, the proliferation of novel genetic engineering technologies has expanded the repertoire of available strains, enabling conditional gene expression, humanized immune responses, and tissue-specific knockouts. This convergence of technical innovation and unmet clinical needs has accelerated preclinical workflows, reshaping research priorities across academia, industry, and clinical settings. Consequently, an understanding of the current mice model landscape is essential for stakeholders seeking to navigate competitive pressures and align their research strategies with emergent trends.

How breakthroughs in genome editing and AI-powered phenotyping are redefining the preclinical research paradigm

The landscape of mice model research is undergoing transformative shifts driven by breakthroughs in genome editing, demand for translational accuracy, and ethical pressures to reduce higher-order mammalian use. CRISPR-Cas9 and related gene-editing platforms have democratized the creation of custom knockouts and humanized models, accelerating timelines and lowering costs. These platforms now coexist with advanced breeding strategies to yield genetically engineered mice that replicate complex human disease signatures.

Meanwhile, the integration of high-throughput phenotyping and in vivo imaging has enhanced the resolution at which researchers monitor disease progression and therapeutic efficacy. Artificial intelligence and machine learning algorithms have begun to sift through enormous data sets generated in these studies, offering predictive insights and facilitating the selection of optimal model types.

Ethical considerations and regulatory scrutiny have further influenced the market, prompting the implementation of rigorous welfare standards and incentivizing the development of alternative assays. As stakeholders navigate these dynamic forces, they must remain agile to leverage innovations that improve translational relevance and operational efficiency.

Navigating the ramifications of US trade measures in 2025 and their profound implications on model sourcing and operational resilience

The introduction and escalation of United States tariffs in 2025 have introduced both challenges and recalibration opportunities for the mice model ecosystem. Tariffs on imported scientific consumables and proprietary breeding stock have elevated costs for model generation, compelling many organizations to reassess their supply chains and vendor portfolios. Research institutions and Contract Research Organizations have sought to mitigate financial burdens by consolidating orders, negotiating long-term supply agreements, and investing in localized breeding facilities.

Despite these headwinds, the tariff environment has also galvanized domestic production capacity, as vendors expand in-country vivaria and streamline licensing processes to meet shifting demand. Consequently, collaborative networks have emerged between academic centers and biotechnology firms to share breeding resources and expertise, fostering resilience against trade uncertainties. Companies that adapt by diversifying sourcing strategies and embracing vertical integration stand to enhance supply security while maintaining rigorous standards of reproducibility.

Uncovering how model type intricacies and application-driven requirements converge to shape distinct research pathways

Diverse research imperatives and funding priorities have driven the segmentation of the mice model market into distinct categories that align with specific experimental needs. Inbred mice strains provide reproducible genetic backgrounds ideal for foundational studies, while outbred models introduce heterogeneity that mirrors human populations and supports toxicology assessments. On the genetically engineered front, conditional knockouts offer temporal and tissue-specific control, transgenic lines express exogenous genes for pathway analysis, knockout models elucidate gene function through full gene removal, and humanized systems recapitulate human immune dynamics.

Application segmentation reveals a broad spectrum of disease and therapeutic domains. Behavioral studies leverage specialized strains to probe neurological function, whereas cardiovascular research benefits from hypertensive and atherosclerotic models. Drug discovery and toxicology demand robust systems for early safety screening, and genetic disease research relies on congenital and metabolic disorder models. Immunology experiments are underpinned by humanized mice, infectious disease research exploits susceptibility variants, neurodegenerative inquiries utilize Alzheimer's and Parkinson's transgenics, and oncology investigations draw upon xenograft and syngeneic tumor systems.

End users range from academic and research institutions driving fundamental science to contract research organizations performing outsourced studies. Hospitals and diagnostic centers integrate preclinical findings into translational initiatives, while pharmaceutical and biotechnology companies depend on these models to advance pipelines from candidate identification through pre-IND safety assessment. Each segment presents unique requirements, procurement cycles, and validation standards that inform tailored service offerings.

Evaluating regional research ecosystems and funding priorities that drive differentiated adoption of murine research platforms

Regional dynamics reveal nuanced patterns in research investment, infrastructure, and collaborative networks across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust funding ecosystems and concentrated biotechnology hubs have cultivated vertically integrated supply chains, enabling rapid adoption of advanced mouse models. North American research consortia and government initiatives foster public-private partnerships that accelerate technology translation.

Across Europe, Middle East & Africa, stringent regulatory frameworks have elevated animal welfare standards, prompting synchronized adoption of refinement techniques and alternative validation methods. Strong academic clusters in Western Europe collaborate with biotech startups to co-develop bespoke strains, while emerging markets in the Middle East and Africa focus on capacity building and training to broaden regional expertise.

The Asia-Pacific region exhibits explosive growth fueled by rising research expenditure, expanding contract research organizations, and government incentives aimed at biotech innovation. China, Japan, and South Korea lead investment in state-of-the-art vivarium infrastructure, whereas Southeast Asian nations emphasize cross-border partnerships and talent development to meet escalating demand for translational models.

Mapping the competitive ecosystem defined by technological leadership and strategic alliances driving murine model innovation

The competitive landscape features specialized vivarium operators, genetic engineering pioneers, and comprehensive service providers that differentiate through technology integration, portfolio breadth, and global reach. Leading laboratory animal suppliers have expanded their genetic archives to encompass rare knockout and humanized lines, complemented by contract breeding services that offer rapid scalability and customized colony management.

Innovators of genome-editing tools have forged partnerships with pharmaceutical giants to co-develop disease models aligned with pipeline priorities, while full-service contract research organizations bundle model provision with in vivo efficacy and toxicological evaluation. Strategic collaborations between academic institutions and commercial entities have accelerated the commercial deployment of new strains, deepening the bench-to-bedside integration.

Companies that invest in digital platforms for colony management and integrate imaging-based phenotyping services have gained a competitive edge by unlocking data-rich insights and fostering reproducibility. As intellectual property considerations intensify, players with robust patent portfolios and licensing frameworks command premium positioning, particularly for next-generation humanized and conditional knockout models.

Outlined strategic directives empowering stakeholders to enhance resilience and accelerate preclinical model innovation

Industry leaders should prioritize investments in localized breeding infrastructure to mitigate trade-related risks and ensure uninterrupted supply. Establishing regional vivarium hubs with scalable capacity will reduce lead times and enhance responsiveness to emergent research projects. Meanwhile, fostering collaborations with genome-editing specialists can streamline the development of bespoke models that match therapeutic pipelines' unique targets.

Organizations must also capitalize on digitalization by adopting cloud-based colony management systems and AI-driven phenotyping platforms. These tools not only bolster data integrity but also accelerate decision-making processes through predictive analytics. Concurrently, proactive engagement with regulatory authorities and ethics committees will help organizations anticipate evolving welfare standards and streamline model approval pathways.

Finally, corporate research divisions, academic centers, and contract organizations should coalesce around consortia that share best practices, breeding resources, and phenotypic databases. Such collaborative networks will dilute operational costs, spur innovation, and cultivate a resilient infrastructure capable of adapting to geopolitical and technological shifts.

Detailing a robust hybrid research framework leveraging primary interviews and comprehensive secondary data validation

Our analysis integrates a multi-layered research methodology composed of primary and secondary data collection, rigorous validation, and triangulation. Initially, secondary sources were examined, encompassing peer-reviewed literature, patent databases, regulatory filings, and industry white papers to establish foundational context and identify emerging trends.

Subsequently, in-depth interviews with key opinion leaders across academia, contract research organizations, and biotechnology firms provided qualitative insights into operational challenges, adoption drivers, and innovation roadblocks. Data gleaned from these discussions underwent cross-verification against commercial intelligence platforms, vendor catalogs, and technical specifications to ensure consistency.

Quantitative data points were subjected to triangulation through comparative analysis of company disclosures, public grant databases, and import-export records. This multi-pronged approach enabled a balanced perspective that accounts for both macro-level influences and micro-level decision criteria. Findings were then synthesized into coherent narratives that reflect current market realities, future inflection points, and actionable intelligence.

Synthesizing insights on collaborative innovation and strategic foresight shaping the future of murine research models

Mice models stand at the confluence of scientific innovation, ethical considerations, and commercial imperatives. The evolving landscape of genome editing, digital phenotyping, and regional investment strategies underscores a market in flux-one characterized by both disruption and opportunity. Stakeholders who proactively address supply-chain vulnerabilities and adopt emerging technologies will be well-positioned to lead the next wave of preclinical breakthroughs.

The cumulative impact of trade policies, shifting funding landscapes, and rising demand for translational fidelity necessitates an agile approach to portfolio planning and infrastructure development. By aligning operational capabilities with cutting-edge scientific advances and regulatory requirements, organizations can ensure sustained relevance and competitive differentiation.

In sum, the trajectory of mice model research hinges on collaboration, innovation, and strategic foresight. Those who master these imperatives will unlock new avenues for therapeutic discovery, augment their research efficiency, and ultimately contribute to meaningful advancements in human health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Mice Model Market, by Model Type

  • 8.1. Genetically Engineered Mice Models
    • 8.1.1. Conditional Knockout Models
    • 8.1.2. Humanized Mice Models
    • 8.1.3. Knockout Models
    • 8.1.4. Transgenic Models
  • 8.2. Inbred Mice Models
  • 8.3. Outbred Mice Models

9. Mice Model Market, by Application

  • 9.1. Behavioral Studies
  • 9.2. Cardiovascular Diseases
  • 9.3. Drug Discovery & Toxicology
  • 9.4. Genetic Disease Research
  • 9.5. Immunology
  • 9.6. Infectious Diseases
  • 9.7. Metabolic Disorders
  • 9.8. Neurology & Neurodegenerative Diseases
  • 9.9. Oncology Research

10. Mice Model Market, by End User

  • 10.1. Academic & Research Institutions
  • 10.2. Contract Research Organizations (CROs)
  • 10.3. Hospitals & Diagnostic Centers
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Mice Model Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Mice Model Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Mice Model Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Mice Model Market

15. China Mice Model Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Applied StemCell, Inc.
  • 16.6. Aragen Life Sciences Ltd.
  • 16.7. Biocytogen Boston Corporation
  • 16.8. Charles River Laboratories International, Inc.
  • 16.9. Creative Biolabs
  • 16.10. Crown Bioscience by JSR Life Sciences, LLC
  • 16.11. Cyagen US Inc. by PolyGene AG
  • 16.12. Envigo by Inotiv, Inc.
  • 16.13. GenOway
  • 16.14. Harbour BioMed
  • 16.15. inGenious Targeting Laboratory, Inc.
  • 16.16. Janvier Labs
  • 16.17. Marshall BioResources
  • 16.18. MD Biosciences
  • 16.19. Mirimus, Inc.
  • 16.20. Ozgene Pty Ltd.
  • 16.21. PhoenixBio Co., Ltd.
  • 16.22. Shanghai Model Organisms Center, Inc.
  • 16.23. Taconic Biosciences, Inc.
  • 16.24. The Jackson Laboratory
  • 16.25. TransCure bioServices
  • 16.26. Translational Drug Development, LLC
  • 16.27. Urosphere SAS
  • 16.28. XenOPAT SL by Bellvitge Biomedical Research Institute

LIST OF FIGURES

  • FIGURE 1. GLOBAL MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MICE MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MICE MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MICE MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MICE MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MICE MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MICE MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MICE MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MICE MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MICE MODEL MARKET SIZE, BY CONDITIONAL KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MICE MODEL MARKET SIZE, BY CONDITIONAL KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICE MODEL MARKET SIZE, BY CONDITIONAL KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICE MODEL MARKET SIZE, BY HUMANIZED MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICE MODEL MARKET SIZE, BY HUMANIZED MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICE MODEL MARKET SIZE, BY HUMANIZED MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICE MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MICE MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MICE MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MICE MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICE MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MICE MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MICE MODEL MARKET SIZE, BY INBRED MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MICE MODEL MARKET SIZE, BY INBRED MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MICE MODEL MARKET SIZE, BY INBRED MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MICE MODEL MARKET SIZE, BY OUTBRED MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MICE MODEL MARKET SIZE, BY OUTBRED MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MICE MODEL MARKET SIZE, BY OUTBRED MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MICE MODEL MARKET SIZE, BY BEHAVIORAL STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MICE MODEL MARKET SIZE, BY BEHAVIORAL STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICE MODEL MARKET SIZE, BY BEHAVIORAL STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICE MODEL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICE MODEL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MICE MODEL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MICE MODEL MARKET SIZE, BY DRUG DISCOVERY & TOXICOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MICE MODEL MARKET SIZE, BY DRUG DISCOVERY & TOXICOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MICE MODEL MARKET SIZE, BY DRUG DISCOVERY & TOXICOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MICE MODEL MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MICE MODEL MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICE MODEL MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MICE MODEL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICE MODEL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MICE MODEL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MICE MODEL MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MICE MODEL MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MICE MODEL MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MICE MODEL MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MICE MODEL MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MICE MODEL MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MICE MODEL MARKET SIZE, BY NEUROLOGY & NEURODEGENERATIVE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MICE MODEL MARKET SIZE, BY NEUROLOGY & NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MICE MODEL MARKET SIZE, BY NEUROLOGY & NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MICE MODEL MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MICE MODEL MARKET SIZE, BY ONCOLOGY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MICE MODEL MARKET SIZE, BY ONCOLOGY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MICE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MICE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MICE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MICE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MICE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MICE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MICE MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICE MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MICE MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MICE MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MICE MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MICE MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MICE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS MICE MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MICE MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GCC MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GCC MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 116. GCC MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. GCC MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. G7 MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. G7 MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 131. G7 MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NATO MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 136. NATO MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NATO MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)